Shocking Drug Price Cut — Big Pharma Steps Up

Stethoscope and prescription pills on a background of dollar bills

What if I told you that the cost of staying alive just got a little bit cheaper?

At a Glance

Bristol Myers Squibb and Pfizer offer a direct-to-patient discount for Eliquis.
The program provides over 40% off the current list price.
Eligible patients in the U.S. can access the program starting September 8, 2025.
The initiative aims to address affordability and access issues in the U.S. healthcare system.

Eliquis: A Lifesaver Gets More Affordable

Imagine needing a lifesaving medication only to find that its cost is sky-high. That’s been the reality for many Eliquis (apixaban) users. Developed by Bristol Myers Squibb and Pfizer, Eliquis is a leading oral anticoagulant, crucial for preventing strokes in patients with nonvalvular atrial fibrillation. Despite its importance, the drug’s high price tag has been a barrier for many, especially those uninsured or underinsured. As of September 8, 2025, there’s a new ray of hope.

On July 17, 2025, Bristol Myers Squibb and Pfizer announced an unprecedented direct-to-patient purchase option for Eliquis. Through the Eliquis 360 Support program, eligible U.S. patients can buy the drug at more than 40% off the current list price. The program aims to bypass traditional insurance hurdles, making the medication more accessible for those who pay cash or have high-deductible plans.

The Driving Forces Behind the Initiative

Why now? Rising drug prices and insurance complexities have long been a thorn in the side of patients and providers alike. With increasing scrutiny over drug pricing transparency, pharmaceutical companies are under pressure to provide direct relief to patients. Bristol Myers Squibb and Pfizer are heeding the call, leveraging their partnership to expand access and maintain Eliquis’ market share. This initiative is a strategic move to address growing affordability concerns and demonstrate responsiveness to patient needs.

The program targets cash-paying patients, offering immediate cost relief and potentially improving medication adherence. By allowing eligible patients in all 50 states and Puerto Rico to directly purchase Eliquis, the companies are setting a new precedent for high-demand medication accessibility. This move could pressure other pharmaceutical giants to adopt similar models, shaking up the industry in the process.

Potential Outcomes and Industry Impact

With the program’s launch, patients stand to benefit the most. Reduced out-of-pocket costs could lead to better health outcomes and increased public goodwill towards Bristol Myers Squibb and Pfizer. Healthcare providers may observe improved adherence and outcomes, while pharmacies and pharmacy benefit managers may face a reduced role in dispensing Eliquis.

Economically, this initiative could lead to a decrease in healthcare costs associated with untreated atrial fibrillation and stroke. Socially, it represents a step towards equity in access to essential medications. Politically, it may influence ongoing debates about drug pricing reform and direct-to-consumer models, potentially prompting regulatory scrutiny or calls for broader adoption of transparent pricing.

Expert Opinions and Future Considerations

Industry experts see this as a significant step towards addressing affordability gaps for essential medications. However, they caution that this model doesn’t tackle underlying systemic issues like overall drug pricing and insurance coverage gaps. While the program is a positive development, broader reforms are necessary to ensure all patients access affordable medications, regardless of insurance status.

Patient advocacy groups welcome the initiative but emphasize the need for systemic price reductions and insurance reforms for a lasting impact. As the pharmaceutical landscape evolves, monitoring patient safety, supply chain integrity, and market impacts will be crucial. This bold step by Bristol Myers Squibb and Pfizer may pave the way for similar initiatives, but it’s only the beginning of a much-needed transformation in drug affordability and access.